Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays

(2012) Xiangmei Wu et al.   AUTOIMMUNITY

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

(2012) Tim F Greten et al.   BMC CANCER

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

(2012) Yu Sawada et al.   OncoImmunology

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells

(2011) Toshiaki Yoshikawa et al.   CANCER SCIENCE

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

(2011) Eishiro Mizukoshi et al.   HEPATOLOGY

Identification of HLA-A*0201- and A*2402-Restricted Epitopes of Mucin 5AC Expressed in Advanced Pancreatic Cancer

(2011) Sadaaki Yamazoe et al.   PANCREAS

Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes

(2009) Uta B. Hofmann et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor

(2009) Tomohide Tsukahara et al.   Journal of Translational Medicine

Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice

(2008) Yoshiaki Ikuta et al.   CANCER SCIENCE

Glypicans

(2008) Jorge Filmus et al.   GENOME BIOLOGY